Curaleaf Fact Sheet Escalates Hostile Bid: Accuses Aurora of Dilutive ATM Sales Below Offer Value
CURLF sits 84% above its 52-week low of $5.4.
Summary
Curaleaf issued a fact sheet rebutting Aurora's criticisms of its US$4.00 hostile bid, alleging Aurora has accelerated dilutive ATM sales below the offer price and that Aurora insiders stand to collect ~10% of the deal value in change-of-control payments.
Key Events · M&A and Partnerships · CURLF
-
Fact Sheet Rebuts Aurora's Circular
Curaleaf issued a fact sheet addressing what it calls misleading statements from Aurora in the hostile takeover contest, defending its US$4.00 per share offer (45% premium, 110% excluding cash).
-
Alleges Accelerated Dilutive ATM Sales
Curaleaf claims Aurora has accelerated At-the-Market share issuances at prices materially below the value implied by Curaleaf's offer since the bid was launched, undercutting Aurora's argument that the offer undervalues the company.
-
No Price Discussions Before Rejection
Curaleaf states Aurora never entered into a confidentiality agreement and never once discussed price before rejecting the proposal, suggesting Aurora's board did not test whether additional value could be secured.
-
Aurora Insider Change-of-Control Payments
Curaleaf discloses that Aurora insiders have ~10% of the transaction value payable in the event of a change in control, a potential conflict of interest for shareholders evaluating the bid.
Analysis · CURLF · Life Sciences
Curaleaf's latest 425 filing is a direct rebuttal to Aurora's Directors' Circular, and it introduces new, specific allegations that could sway shareholder sentiment in the hostile takeover contest. The most consequential claim is that Aurora has accelerated dilutive ATM share issuances at prices materially below the US$4.00 offer value since Curaleaf's bid — if true, this undercuts Aurora's argument that the offer undervalues the company and suggests management is selling stock at prices it tells shareholders to reject. Curaleaf also reveals that Aurora never discussed price or signed a confidentiality agreement before rejecting the bid, and that Aurora insiders stand to receive ~10% of the transaction value in change-of-control payments — a potential conflict of interest that could draw shareholder scrutiny. The fact sheet frames the US$5.00 cap as a 92nd-percentile premium and challenges Aurora's board to shorten the bid period from 105 to 35 days, escalating pressure tactics. This is the fourth 425 filing in the contest, but the new ATM acceleration claim and insider payment disclosure are material deltas that could move the needle for Aurora shareholders deciding whether to tender.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CURLF was trading at $9.96 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.6B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.